Anthony Olson was diagnosed with Myelodysplastic syndromes (MDS) and went on to receive chemo for almost a decade to treat ...

After he was diagnosed, Olson dropped out of college, moved back in with his parents, and began Weiner's prescribed regimen: ...

Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk ...

Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.

Luspatercept significantly improved hemoglobin levels in non-transfusion-dependent patients with lower-risk myelodysplastic ...

Did you know Robin Roberts’ openness about her health journey led to an astounding 1,800% increase in bone marrow donor ...

Huntsman Cancer Institute joins other institutions in myeloMATCH, a program that matches patients with clinical trials that ...

Huntsman Cancer Institute at the University of Utah (the U) has joined other institutions in an innovative clinical trials ...

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes (MDS) and myelofibrosis (MF).